Astec Lifesciences
- P/E
- Not meaningful: loss-making over the last twelve months
Key Fundamentals
MicrocapFertilizers & AgrochemicalsChemicalsPrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- −5.44%
- Debt to Equity
- 1.15
- EPS (TTM)
- −₹29.89
- Book Value
- ₹150.24
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 3.78
- ROE
- −25.20%
- Dividend Yield
- 0.27%
- EBITDA
- ₹50.00 L
- 52W High
- ₹941.75
- 52W Low
- ₹513.40
- Day Range
- ₹548.00 – ₹577.05
- Volume
- 57,919
Peer Comparison
Commodities › Chemicals › Pesticides & Agrochemicals
| ₹529.00 | 22.09 | ₹43,728 Cr | 1.28 | 1.16% | 5.64% | 10.10% | ₹52,804 Cr | ₹2,323 Cr | |
| ₹2,187.00 | 28.48 | ₹33,248 Cr | 2.95 | 0.69% | 11.20% | 15.00% | ₹6,516 Cr | ₹1,164 Cr | |
| ₹328.10 | 28.24 | ₹15,980 Cr | 4.43 | 0.41% | 17.60% | 23.50% | ₹3,192 Cr | ₹581 Cr | |
| ₹3,249.90 | 19.95 | ₹14,602 Cr | 4.92 | 4.57% | 23.70% | 29.10% | ₹5,595 Cr | ₹733 Cr | |
| ₹677.95 | 9.77 | ₹6,015 Cr | 1.88 | 2.23% | 23.20% | 30.20% | ₹5,357 Cr | ₹626 Cr | |
| ₹942.75 | 15.83 | ₹4,217 Cr | 2.50 | 0.21% | 18.50% | 23.80% | ₹1,953 Cr | ₹268 Cr | |
| ₹189.67 | 17.23 | ₹3,734 Cr | 1.68 | 1.58% | 10.20% | 14.10% | ₹2,962 Cr | ₹214 Cr | |
| Astec Lifesciences (this company) | ₹567.40 | — | ₹1,234 Cr | 3.78 | 0.27% | −25.20% | −5.44% | ₹441 Cr | −₹67 Cr |
| Median 8 companies | ₹622.68 | 19.95 | ₹10,309 Cr | 2.73 | 0.93% | 14.40% | 19.25% | ₹4,275 Cr | ₹604 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 91/100
Category scores
- Quality
- 14
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 21
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 47
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 19
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 18
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 56
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
7- Stock is trading at 4.05 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -4.18% over past five years.
- Company has a low return on equity of -26.0% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.3.21 Cr.
- Company has high debtors of 202 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 4 | 3 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 32.65
- Neutral
- MACD (12,26,9)
- −36.58
- Bearish
- SMA (50)
- 663.58
- Bearish
- SMA (200)
- 663.19
- Bearish
As of
Analyst Rating
0 of 1 analyst rates Buy, 0 Hold, 1 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +6.76% |
|---|---|
| 5Y | −4.19% |
| 3Y | −10.65% |
| 1Y | +17.59% |
| TTM | +9.41% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Turned to loss |
| 3Y | Turned to loss |
| 1Y | Loss narrowed by ₹54 Cr |
| TTM | Loss narrowed by ₹61 Cr |
Operating cash flow
| 10Y | Outflow widened by ₹68 Cr |
|---|---|
| 5Y | Outflow widened by ₹73 Cr |
| 3Y | Turned negative |
| 1Y | Outflow widened by ₹73 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −14.62 pp |
|---|---|
| 5Y | −21.07 pp |
| 3Y | −13.15 pp |
| 1Y | +16.43 pp |
| TTM | +8.80 pp |
Revenue by year
| Mar 2017 | ₹299 Cr |
|---|---|
| Mar 2018 | ₹368 Cr |
| Mar 2019 | ₹431 Cr |
| Mar 2020 | ₹523 Cr |
| Mar 2021 | ₹555 Cr |
| Mar 2022 | ₹677 Cr |
| Mar 2023 | ₹628 Cr |
| Mar 2024 | ₹458 Cr |
| Mar 2025 | ₹381 Cr |
| Mar 2026 | ₹448 Cr |
Net profit by year
| Mar 2017 | ₹19.00 Cr |
|---|---|
| Mar 2018 | ₹35.00 Cr |
| Mar 2019 | ₹36.00 Cr |
| Mar 2020 | ₹48.00 Cr |
| Mar 2021 | ₹65.00 Cr |
| Mar 2022 | ₹90.00 Cr |
| Mar 2023 | ₹26.00 Cr |
| Mar 2024 | −₹47.00 Cr |
| Mar 2025 | −₹135 Cr |
| Mar 2026 | −₹81.00 Cr |
Analyst Forecasts
Analyst consensus here uses a different definition from reported ebitda (they differ 49.2× on periods where both exist), so the forecast is shown on its own rather than joined to the reported line.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 143 | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 | 72 |
| Expenses | 140 | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 | 80 | 121 | 149 | 84 | 92 |
| Operating Profit | 3 | −3 | −18 | 13 | −46 | −20 | −6 | 6 | −11 | −7 | 4 | 9 | −1 | −20 |
| OPM % | 2.2% | −3.1% | −36% | 8% | −67% | −20% | −6% | 4.6% | −12% | −9% | 3.2% | 6% | −0.8% | −27% |
| Other Income | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | −1 | 3 | 1 | 1 |
| Interest | 6 | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 | 8 | 7 | 8 | 8 | 7 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 | 10 | 11 | 12 | 11 | 11 |
| PBT | −11 | −18 | −32 | −1 | −62 | −39 | −25 | −16 | −33 | −24 | −16 | −8 | −19 | −37 |
| Tax % | −26% | −24% | −24% | 4% | −36% | 0% | 61% | 3% | 0% | 0% | 0% | −2% | 0% | 0% |
| Net Profit | −8 | −13 | −24 | −1 | −40 | −39 | −40 | −16 | −33 | −24 | −16 | −8 | −19 | −37 |
| EPS (₹) | −3.66 | −6 | −10.86 | −0.43 | −17.73 | −17.21 | −18.03 | −7.18 | −14.75 | −10.96 | −7.05 | −3.48 | −8.4 | — |
Sep 2026: from the results filed on 26 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 | 441 |
| Expenses | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | 453 | 435 |
| Operating Profit | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | −6 | −66 | −4 | 6 |
| OPM % | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | −1.3% | −17% | −1% | 1.3% |
| Other Income | −16 | 4 | −8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 3 | 3 |
| Interest | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 35 | 31 |
| Depreciation | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 | 44 |
| PBT | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | −62 | −141 | −81 | −67 |
| Tax % | −17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | −24% | −4% | 0% | — |
| Net Profit | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | −47 | −135 | −81 | −67 |
| EPS (₹) | 6.66 | 2.24 | 8.57 | 15.65 | 16.03 | 21.21 | 29.04 | 40.12 | 11.41 | −20.95 | −60.16 | −36.32 | −29.89 |
| Div. Payout % | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
| Reserves | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 | 368 |
| Borrowings | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | 449 |
| Other Liabilities | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | 102 |
| Total Liabilities | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
| Fixed Assets | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 459 |
| CWIP | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | 463 |
| Total Assets | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 7 | −13 | 19 | 65 | 15 | 168 | −8 | 24 | 75 | 10 | −8 | −81 |
| Investing | −19 | −17 | −18 | −49 | −52 | −74 | −73 | −104 | −113 | −135 | −15 | −4 |
| Financing | 12 | 31 | −1 | −18 | 37 | −95 | 81 | 80 | 38 | 125 | 24 | 94 |
| Net Cash Flow | 0 | 2 | 1 | −3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Free Cash Flow | −13 | −39 | −1 | 15 | −37 | 123 | −111 | −80 | −42 | −125 | −24 | −86 |
| CFO/EBITDA | 19 | −24 | 41 | 116 | 41 | 219 | 13 | 34 | 104 | −211 | 20 | 1,796 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 | 202 |
| Inventory Days | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 | 169 |
| Days Payable | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 | 107 |
| Cash Conversion Cycle | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 | 263 |
| Working Capital Days | 19 | −28 | 1 | −8 | −2 | 8 | 4 | 12 | −17 | −1 | −26 | −56 |
| ROCE % | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | −4% | −13% | −5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Astec Lifesciences insights
64 extracted metrics across FY11–FY27.
Documents
- Q2 FY23 concall · Nov 2022Transcript
- Q2 FY23 concall · Nov 2022Transcript
- Q4 FY22 concall · May 2022Transcript
- Q2 FY22 concall · Nov 2021Transcript
- Q1 FY22 concall · Aug 2021Transcript
- 26 Oct 2026
- 27 Apr 2026
- 30 Jan 2026
- 10 Jun 2026
- 24 Mar 2026
- 11 Jun 2025
- 25 Mar 2025
- 7 Aug 2024
- General announcements 26 Oct 2026
- General announcements 8 Oct 2026
Frequently Asked Questions about Astec Lifesciences
What does Astec Lifesciences Ltd do?
Where is Astec Lifesciences Ltd (ASTEC) listed?
Which sector does Astec Lifesciences Ltd belong to?
What is the 52-week high and low of Astec Lifesciences Ltd?
Does Astec Lifesciences Ltd pay dividends?
What is the Return on Equity (ROE) of Astec Lifesciences Ltd?
Company Information
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries. Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ASTEC.md for Astec Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.